



# **Effect of Ranibizumab Treatment in Cases of Choroidal Neovascular Membranes Secondary to Pathological Myopia versus Age-Related Macular Degeneration**

Thesis

*Submitted for Partial Fulfillment  
of Master Degree in Ophthalmology*

By

***Mohammed Shaalan Abd Al-Tawab***  
*M.B.B.Ch*

Under Supervision of

**Prof. Dr. Zafer Fahim Ismail**

*Professor of Ophthalmology  
Faculty of Medicine–Ain Shams University*

**Dr. Weam Mohamed Ahmed Ebeid**

*Assistant Professor of Ophthalmology  
Faculty of Medicine–Ain Shams University*

**Dr. Samah Mahmoud Fawzy**

*Lecturer of Ophthalmology  
Faculty of Medicine–Ain Shams University*

*Faculty of Medicine–Ain Shams University  
Cairo– 2019*

بِسْمِ اللّٰهِ الرَّحْمٰنِ الرَّحِیْمِ

وَأَنْزَلَ اللّٰهُ عَلَيْكَ  
الْكِتَابَ وَالْحِكْمَةَ  
وَعَلَّمَكَ مَا لَمْ  
تَكُن تَعْلَمُ وَكَانَ  
فَضْلُ اللّٰهِ عَلَيْكَ  
عَظِيمًا

صدق الله العظيم

سورة النساء آية (١١٣)

## Acknowledgments

*First and foremost, I feel always indebted to **Allah** the Most Beneficent and Merciful.*

*I wish to express my deepest thanks, gratitude and appreciation to **Prof. Dr. Zafer Fahim Ismail**, Professor of Ophthalmology, Faculty of Medicine, Ain Shams University, for his meticulous supervision, kind guidance, valuable instructions and generous help.*

*Special thanks are due to **Dr. Weam Mohamed Ahmed Ebeid**, Assistant Professor of Ophthalmology, Faculty of Medicine, Ain Shams University, for her sincere efforts, fruitful encouragement.*

*I am deeply thankful to **Dr. Samah Mahmoud Fawzy**, Lecturer of Ophthalmology, Faculty of Medicine, Ain Shams University, for her great help, outstanding support, active participation and guidance.*

*I would like to express my hearty thanks to all my family especially my wife, my sons, my father and my mother for their support till this work was completed.*

**Mohammed Shaalan Abd Al-Jawab**

# List of Contents

Title	Page No.
List of Tables .....	5
List of Figures .....	6
List of Abbreviations.....	9
Introduction.....	- 1 -
Aim of the Work .....	14
Review of Literature	
▪ Anatomy and Physiology of the Retina.....	15
▪ Age Related Macular Degeneration .....	26
▪ Myopic Choroidal Neovascularization .....	53
▪ Ranibizumab .....	61
Patients and Methods .....	64
Results .....	70
Discussion.....	79
Summary and Conclusion.....	85
References .....	88
Arabic Summary	

# List of Tables

Table No.	Title	Page No.
<b>Table (1):</b>	Clinical classification for AMD.....	28
<b>Table (2):</b>	Mean pre and post injection VA (Log Mar) at follow up. ....	72
<b>Table (3):</b>	Mean pre and post injection CMT ( $\mu\text{m}$ ) at follow up. ....	74
<b>Table (4):</b>	Mean pre and post injection AT ( $\mu\text{m}$ ) at follow up. ....	76
<b>Table (5):</b>	Mean pre and post injection TV at follow up. ....	78

# List of Figures

Fig. No.	Title	Page No.
<b>Figure (1):</b>	Retinal cells and synapses. The 10 retinal layers are indicated .....	16
<b>Figure (2):</b>	Schematic showing regions of retina and corresponding histologic architecture .....	17
<b>Figure (3):</b>	OCT scan of left macular area, retinal layers can be visualized; foveal indentation clearly evident.....	18
<b>Figure (4):</b>	Drawing showing vasculature of the retina and choroid.....	19
<b>Figure (5):</b>	Histology of choroidal layers .....	23
<b>Figure (6):</b>	Layers of Bruch's membrane, delineated on basis of electron microscope studies .....	25
<b>Figure (7):</b>	Pathological changes in neovascular AMD .....	31
<b>Figure (8):</b>	Serous PED in an AMD patient.....	35
<b>Figure (9):</b>	Grayish choroidal neovascular membrane .....	35
<b>Figure (10):</b>	RPE alteration .....	36
<b>Figure (11):</b>	Disciform scar .....	36
<b>Figure (12):</b>	Color images of (upper left panel), early phase (upper right panel), mid-phase (lower left panel), and late phase fluorescein angiogram (lower right panel) of a patient with a classic CNV lesion .....	38
<b>Figure (13):</b>	Color images of (upper left panel), early phase (upper right panel), mid-phase (lower left panel), and late phase fluorescein angiogram (lower right panel) of a patient with an occult CNV lesion .....	40

## List of Figures cont...

Fig. No.	Title	Page No.
<b>Figure (14):</b>	RAP staging system.....	41
<b>Figure (15):</b>	Color images of (upper left panel), early phase (upper right panel), mid-phase (lower left panel), and late phase fluorescein angiogram (lower right panel) of a patient with a RAP lesion .....	42
<b>Figure (16):</b>	Long-term monthly SD-OCT monitoring of a high-risk patient .....	44
<b>Figure (17):</b>	Cross-sectional image showing a classic CNV, type 2 neovascularization, delineated as a non-uniform moderately hyper-reflective formation above the RPE (asterisk) and the presence of intraretinal cysts (arrowhead).....	45
<b>Figure (18):</b>	OCT shows a hyper-reflective area within the retina, thought to represent the RAP lesion .....	46
<b>Figure (19):</b>	Features of PCV on SD-OCT.....	47
<b>Figure (20):</b>	PCV, predominantly peripapillary.....	48
<b>Figure (21):</b>	Intraretinal cysts caused by active leakage in Active type I CNV with fibrovascular PED .....	49
<b>Figure (22):</b>	Type II CNV lesion with associated disruption of the photoreceptor layers.....	50
<b>Figure (23):</b>	Comparison of fibrovascular versus serous PED .....	52
<b>Figure (24):</b>	OCT of CNV one month following treatment with intravitreal anti-VEGF therapy with resultant RPE tear .....	52

## List of Figures cont...

Fig. No.	Title	Page No.
<b>Figure (25):</b>	Active myopic choroidal neovascularisation (CNV) imaged via (A) colour fundus photography .....	58
<b>Figure (26):</b>	FA in the right eye (4 minutes, 48 seconds) .....	59
<b>Figure (27):</b>	Case of a 65-year-old female patient presenting with high myopia with drusen and choroidal neovascularization .....	60
<b>Figure (28):</b>	Relationship between Ranibizumab and Bevacizumab .....	62
<b>Figure (29):</b>	Topcon 3D OCT-2000 FA device .....	66
<b>Figure (30):</b>	Topcon 3D OCT-2000 FA menu. ....	66
<b>Figure (31):</b>	Perpendicular entry of the needle into the vitreous cavity .....	68
<b>Figure (32):</b>	Comparison between pre and post-injection VA values along the period of follow up. ....	72
<b>Figure (33):</b>	Comparison between pre and post-injection CMT values along the period of follow up. ....	74
<b>Figure (34):</b>	Comparison between pre and post-injection AT values along the period of follow up.....	76
<b>Figure (35):</b>	Comparison between pre and post-injection TV values along the period of follow up.....	78

# List of Abbreviations

Abb.	Full term
<i>AEs</i> .....	<i>Adverse events</i>
<i>AMD</i> .....	<i>Age-related macular degeneration</i>
<i>AREDS</i> .....	<i>Age-related eye disease study</i>
<i>AT</i> .....	<i>Average thickness</i>
<i>BM</i> .....	<i>Bruch's membrane</i>
<i>CFT</i> .....	<i>Central foveal thickness</i>
<i>CME</i> .....	<i>Cystoid macular edema</i>
<i>CMT</i> .....	<i>Central macular thickness</i>
<i>CNV</i> .....	<i>Choroidal neovascularization</i>
<i>CNVM</i> .....	<i>Choroidal neovascular membrane</i>
<i>CRA</i> .....	<i>Chorioretinal atrophy</i>
<i>FAZ</i> .....	<i>Foveal avascular zone</i>
<i>FFA</i> .....	<i>Fundus fluorescein angiography</i>
<i>GA</i> .....	<i>Geographic atrophy</i>
<i>HRDs</i> .....	<i>Hyper-reflective dots</i>
<i>ICG</i> .....	<i>Indocyanine green</i>
<i>IOP</i> .....	<i>Intraocular pressure</i>
<i>MCNV</i> .....	<i>Myopic choroidal neovascularization</i>
<i>OCT</i> .....	<i>Optical coherence tomography</i>
<i>PCV</i> .....	<i>Polypoidal choroidal vasculopathy</i>
<i>PDT</i> .....	<i>Photodynamic therapy</i>
<i>PED</i> .....	<i>Pigment epithelial detachment</i>
<i>PEDF</i> .....	<i>Pigment epithelial derived factor</i>
<i>PLGF</i> .....	<i>Placental growth factor</i>

## List of Abbreviations *cont...*

Abb.	Full term
<i>PRN</i> .....	<i>Pro re nata</i>
<i>RAP</i> .....	<i>Retinal angiomatous proliferation</i>
<i>RPE</i> .....	<i>Retinal pigment epithelium</i>
<i>SD-OCT</i> .....	<i>Spectral Domain Optical Coherence Tomography</i>
<i>SRF</i> .....	<i>Subretinal fluid</i>
<i>TV</i> .....	<i>Total volume</i>
<i>VA</i> .....	<i>Visual acuity</i>
<i>VEGF</i> .....	<i>Vascular endothelial growth factor</i>
<i>VEGFR</i> .....	<i>Vascular endothelial growth factor receptor</i>
<i>VMA</i> .....	<i>Vitreomacular adhesion</i>

## INTRODUCTION

Pathological myopia is a major cause of legal blindness in many developed and developing countries. It is associated with progressive elongation of the globe, which may be accompanied by degenerative changes in the sclera, choroid, Bruch's membrane, retinal pigment epithelium (RPE), and neurosensory retina. The most common vision-threatening complication of pathological myopia is the development of choroidal neovascularization (CNV) at the macula. In many countries, pathological myopia is the commonest cause of CNV in younger patients (*Hampton et al., 1983*).

Age-related macular degeneration (AMD), also known as age-related maculopathy (ARM), is a degenerative disorder affecting the macula of elderly patients. It is characterized by the presence of specific clinical findings including drusen and retinal pigment epithelium (RPE) changes as early features with no evidence that the signs are secondary to another disorder. Later stages of the disease are associated with impairment of vision (*Bowling, 2016*).

**Conventionally AMD is divided into two main types:**

- *Dry (non-exudative) AMD* is the most common form, comprising around 90% of diagnosed disease; geographic atrophy (GA) is the advanced stage of dry AMD (*Bowling, 2016*).

- ***Wet (exudative) AMD*** is much less common than dry, but is associated with more rapid progression to advanced sight loss. The main manifestations are Choroidal neovascularization (CNV) and pigment epithelial detachment (PED). Occasionally, the dry form can develop into the wet form (***Bowling, 2016***).

The disease virtually always begins as the non-neovascular or dry form of AMD and may progress to geographic atrophy or the neovascular (wet) form of the disease in one or both eyes. When neovascularization occurs, there is accumulation of fluid, hemorrhage, and lipid exudation within the macula that can culminate in fibrosis referred to as a disciform scar (***Zarbin et al., 2004***).

AMD is the leading cause of irreversible visual impairment among the elderly worldwide affecting 30–50 million individuals (***de Jong et al. 2006***). The cause of AMD is multifactorial and influenced by age, ethnic background, and a combination of environmental and genetic factors (***Zarbin, 2004***).

Up till now there is no effective medical treatment for AMD; however, vitamin supplementation, good nutrition, and cessation of smoking can slow the progression of the dry form of AMD (***Bressler et al., 2003***), while drugs that inhibit vascular endothelial growth factor-A (VEGF-A) have been successful in converting the wet form of AMD back to the dry form (***Brown et al., 2006***).

CNV refers to the growth of neovasculature derived from the choroidal vessels through breaks in Bruch's membrane into the sub-retinal pigment epithelium or sub-retinal space. CNV is associated with a number of disorders, but the most important one is AMD (*Bai et al., 2014*).

The principle test to diagnose CNV is fluorescein angiography (FFA). Spectral domain optical coherence tomography (SDOCT) is used to help guide clinical management of neovascular AMD patients by providing a cross-sectional view of the retinal depth, visualization of subretinal fluid (SRF), and quantitative measurement of central subfield thickness (CST) (*Mohammad et al., 2014*).

Photocoagulation and photodynamic therapy (PTD), were the conventional lines of treatment of CNV until focus was directed to other causes that attribute to the formation of CNV particularly the effect of vascular endothelial growth factor (VEGF), which binds to endothelial cell receptors, promoting angiogenesis and vascular leakage (*Bowling, 2016*).

Ranibizumab (Lucentis®, Novartis Pharma AG, Switzerland) is a recombinant, humanized, monoclonal antibody fragment designed to inhibit the active forms of vascular endothelial growth factor A (VEGF-A). VEGF-A is important in the pathogenesis of CNV, stimulating the growth of new blood vessels and increasing vascular leakage (*Claxton et al., 2014*).

## **AIM OF THE WORK**

The aim of this work is to compare the response of treatment with ranibizumab in cases of CNV secondary to pathological myopia versus CNV secondary to age-related macular degeneration by using OCT and FFA.

*Chapter 1*

# **ANATOMY AND PHYSIOLOGY OF THE RETINA**

## **Anatomy of the retina**

### *Layers of the retina*

The retina consists of 10 layers, which are actually a remarkable organization of alternate groupings of the retinal neurons and their processes (Fig. 1):

1. Retinal pigment epithelium (RPE)
2. Photoreceptor cell layer
3. External limiting membrane
4. Outer nuclear layer (ONL)
5. Outer plexiform layer (OPL)
6. Inner nuclear layer (INL)
7. Inner plexiform layer (IPL)
8. Ganglion cell layer (GCL)
9. Nerve fiber layer (NFL)
10. Internal limiting membrane (ILM)

*(VanPutte et al., 2014)*